327 related articles for article (PubMed ID: 26080292)
1. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa.
Farinde A
Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292
[No Abstract] [Full Text] [Related]
2. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients].
Pierart F
Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205
[TBL] [Abstract][Full Text] [Related]
3. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J
Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549
[TBL] [Abstract][Full Text] [Related]
4. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798
[No Abstract] [Full Text] [Related]
5. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
Cheer SM; Waugh J; Noble S
Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
[TBL] [Abstract][Full Text] [Related]
6. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
Blasi F; Carnovale V; Cimino G; Lucidi V; Salvatore D; Messore B; Bartezaghi M; Muscianisi E; Porpiglia PA;
Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
[TBL] [Abstract][Full Text] [Related]
7. Inhaled tobramycin (TOBI).
Bonsignore CL
Pediatr Nurs; 1998; 24(3):258-9. PubMed ID: 9987427
[TBL] [Abstract][Full Text] [Related]
8. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
[TBL] [Abstract][Full Text] [Related]
9. [Use of inhaled tobramycin in patients with cystic fibrosis].
Chermenskiĭ AG; Gembitskaia TE
Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
[TBL] [Abstract][Full Text] [Related]
10. Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin.
Barry PJ; Jones AM
J Cyst Fibros; 2014 Dec; 13(6):754. PubMed ID: 24795286
[No Abstract] [Full Text] [Related]
11. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
Chuchalin A; Amelina E; Bianco F
Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
[TBL] [Abstract][Full Text] [Related]
12. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
Somayaji R; Parkins MD
Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacology study of Bramitob, a tobramycin solution for nebulization, in comparison with Tobi.
Poli G; Acerbi D; Pennini R; Soliani Raschini A; Corrado ME; Eichler HG; Eichler I
Paediatr Drugs; 2007; 9 Suppl 1():3-9. PubMed ID: 17536870
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
[TBL] [Abstract][Full Text] [Related]
15. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Parkins MD; Elborn JS
Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
[TBL] [Abstract][Full Text] [Related]
16. Early Pseudomonas aeruginosa colonisation in cystic fibrosis patients.
Marchetti F; Candusso M; Faraguna D; Assael BM
Lancet; 2002 Feb; 359(9306):626-7. PubMed ID: 11867141
[No Abstract] [Full Text] [Related]
17. Tobramycin inhalation solution (Bethkis) for cystic fibrosis.
Med Lett Drugs Ther; 2014 Jun; 56(1445):51-2. PubMed ID: 24956309
[No Abstract] [Full Text] [Related]
18. The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.
Tappenden P; Harnan S; Uttley L; Mildred M; Walshaw M; Taylor C; Brownlee K
Pharmacoeconomics; 2014 Feb; 32(2):159-72. PubMed ID: 24338264
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis upper airways primary colonization with Pseudomonas aeruginosa: eradicated by sinonasal antibiotic inhalation.
Mainz JG; Michl R; Pfister W; Beck JF
Am J Respir Crit Care Med; 2011 Nov; 184(9):1089-90. PubMed ID: 22045752
[No Abstract] [Full Text] [Related]
20. Budget impact model of tobramycin inhalation solution for treatment of Pseudomonas aeruginosa in cystic fibrosis patients.
Woodward TC; Brown R; Sacco P; Zhang J
J Med Econ; 2010; 13(3):492-9. PubMed ID: 20670159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
